Breaking News

Shots Fired at Canada War Memorial, Soldier Down
Tweet TWEET

Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast

    Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and
 Operating Results, and Host Conference Call and Webcast on February 28, 2013

PR Newswire

CHAPEL HILL, N.C., Feb. 21, 2013

CHAPEL HILL, N.C., Feb. 21, 2013 /PRNewswire/ -- Cempra, Inc.(Nasdaq: CEMP)
today announced that it will report fourth quarter and full year 2012
financial results and provide a business update after the close of U.S.
financial markets onFebruary 28, 2013.Prabhavathi Fernandes, Ph.D.,
president and chief executive officer ofCemprawill host a conference call
and webcast at4:30 p.m. EST,February 28, 2013.

The conference call may be accessed by dialing 877-377-7553 for domestic
callers and 253-237-1151 for international callers. Please specify to the
operator that you would like to join the "Cempra, Inc., Fourth Quarter and
Full Year 2012 Financial Results Call, conference ID#: 12497222." The
conference call will be webcast live under the investor relations section
ofCempra's website atwww.cempra.com, and will be archived there for 30 days
following the call. Please visitCempra's website several minutes prior to the
start of the broadcast to ensure adequate time for any software download that
may be necessary.

AboutCempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in the
treatment of bacterial infectious diseases. Cempra's two lead product
candidates are in advanced clinical development; solithromycin in Phase 3 for
CABP and TAKSTA™ (CEM-102) in Phase 2 for prosthetic joint infections. Both
seek to address the need for new treatments targeting drug-resistant bacterial
infections in the hospital and in the community. The company also intends to
use its series of proprietary lead compounds from its novel macrolide library
for uses such as the treatment of chronic inflammatory diseases, endocrine
diseases and gastric motility disorders. Additional information about Cempra
can be found at www.cempra.com.

Investor and Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Andreas Marathovouniotis
Russo Partners, LLC
(212) 845-4235
Andreas.marathis@russopartnersllc.com

SOURCE Cempra, Inc.

Website: http://www.cempra.com
 
Press spacebar to pause and continue. Press esc to stop.